Shopping Cart
Remove All
Your shopping cart is currently empty
Ravagalimab (Synonyms: ABBV-323, ABBV323)
Catalog No. T77143 Copy Product Info
Purity: 95%
🥰Excellent
Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS). Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation.
Ravagalimab
Copy Product Info🥰Excellent
Catalog No. T77143
Synonyms ABBV-323, ABBV323
Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS). Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation.
Ravagalimab
Cas No. 2050816-56-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $262 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,570 | - | In Stock | |
| 25 mg | $2,330 | - | In Stock | |
| 50 mg | $3,130 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.9% (SDS-PAGE); 99.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS). Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation. |
| Targets&IC50 | CD40:3.7 nM (EC50) |
| In vitro | Ravagalimab (0-100 nM, 2 days) treatment of primary Homo sapiens B cells inhibited the upregulation of CD86 with an EC50 of 0.6 nM. [2] |
| Synonyms | ABBV-323, ABBV323 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF5/CD40 |
| Molecular Weight | 145.95 kDa |
| Cas No. | 2050816-56-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Ravagalimab | purchase Ravagalimab | Ravagalimab cost | order Ravagalimab | Ravagalimab in vitro | Ravagalimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.